Table 3.
Genotype and allele frequency of rs72618599 SNP in relation to clinical features of GC patients
| Variable | No. of genotype (%) | No. of allele (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Total (%) | CC | CT | TT | p value | Total (%) | C | T | p value | |
| Blood group | 0.026a | 0.554 | |||||||
| A+ | 46 (39.66) | 24 (40.0) | 20 (50.0) | 2 (12.5) | 92 (39.66) | 68 (42.5) | 24 (33.3) | ||
| B+ | 20 (17.24) | 12 (20.0) | 4 (10.0) | 4 (25.0) | 40 (17.24) | 28(17.5) | 12 (16.7) | ||
| B- | 2 (1.73) | 0 (0) | 2 (5.0) | 0 (0) | 4 (1.72) | 2 (1.2) | 2 (2.8) | ||
| O+ | 30 (25.86) | 14 (23.3) | 12 (30.0) | 4 (25.0) | 60 (25.86) | 40 (25.0) | 20 (27.8) | ||
| O- | 6 (5.17) | 2 (3.3) | 2 (5.0) | 2 (12.5) | 12 (5.18) | 6 (3.8) | 6 (8.3) | ||
| AB | 12 (10.34) | 8 (13.4) | 0 (0) | 4 (25.0) | 24 (10.34) | 16 (10.0) | 8 (11.1) | ||
| Smoking | 0.364 | 0.314 | |||||||
| Positive | 40 (60.6) | 22 (68.8) | 12 (50.0) | 6 (60.0) | 80 (60.6) | 56 (63.6) | 24 (54.5) | ||
| Negative | 26 (39.4) | 10 (31.2) | 12 (50.0) | 4 (40.0) | 52 (39.4) | 32 (36.4) | 20 (45.5) | ||
| H.pylori | 0.382 | 0.008a | |||||||
| Positive | 29 (53.7) | 11 (37.9) | 8 (27.6) | 10 (34.5) | 58 (59.79) | 30 (51.7) | 28 (48.3) | ||
| Negative | 25 (46.3) | 11 (44.0) | 12 (48.0) | 2 (8.0) | 39 (40.21) | 23 (59.0) | 16 (41.0) | ||
| Primary tumor status | 0.113 | 0.017a | |||||||
| I | 2 (2.17) | 0 (0) | 0 (0) | 2 (12.5) | 4 (2.17) | 0 (0) | 4 (7.4) | ||
| II | 32 (34.78) | 20 (37.0) | 8 (36.3) | 4 (25.0) | 64 (34.78) | 48 (36.9) | 16 (29.6) | ||
| III | 44 (47.83) | 26 (48.2) | 10(45.5) | 8 (50.0) | 88 (47.83) | 62 (47.7) | 26 (48.2) | ||
| IV | 14 (15.22) | 8 (14.8) | 4 (18.2) | 2 (12.5) | 28 (15.22) | 20 (15.4) | 8 (14.8) | ||
| Lymph node status | 0.023a | 0.017a | |||||||
| 0 | 16 (17.77) | 12 (24.0) | 0 (0) | 4 (25.0) | 32 (16.84) | 24 (19.4) | 8 (12.1) | ||
| I | 32 (35.56) | 18 (36.0) | 8 (33.3) | 6 (37.5) | 74 (38.95) | 44 (35.5) | 30 (45.5) | ||
| II | 24 (26.67) | 8 (16.0) | 10 (41.7) | 6 (37.5) | 48 (25.26) | 26 (21.0) | 22 (33.3) | ||
| III | 18 (20) | 12 (24.0) | 6 (25.0) | 0 (0) | 36 (18.95) | 30 (24.1) | 6 (9.1) | ||
| Tumor stage | 0.150 | 0.105 | |||||||
| I | 14 (11.86) | 8 (11.8) | 2 (6.2) | 4 (22.2) | 28 (11.67) | 18 (10.7) | 10 (13.9) | ||
| II | 24 (20.34) | 14 (20.6) | 6 (18.8) | 4 (22.2) | 48 (20) | 34 (20.2) | 14 (19.4) | ||
| III | 36 (30.51) | 16 (23.5) | 12 (37.5) | 8 (44.4) | 72 (30) | 44 (26.2) | 28 (38.9) | ||
| IV | 44 (37.29) | 30 (44.1) | 12 (37.5) | 2 (11.2) | 92 (38.33) | 72 (42.9) | 20 (27.8) | ||
| Metastasis | 0.067 | 0.044a | |||||||
| Positive | 66 (57) | 36 (52.9) | 18 (52.9) | 12 (85.7) | 132 (56.9) | 90 (52.9) | 42 (67.7) | ||
| Negative | 50 (43) | 32 (47.1) | 16 (47.1) | 2 (14.3) | 100 (43.1) | 80 (47.1) | 20 (32.3) | ||
a p < 0.05